Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|April 1, 2014

BioPharm International

  • BioPharm International-04-01-2014
  • Volume 27
  • Issue 4

Liquid Chromatography Column Separates Glycans

Liquid Chromatography Column Separates Glycans

Thermo Fisher Scientific’s GlycanPac AXR-1 columns are designed for increased resolution of labeled and unlabeled glycans, and are compatible with fluorescence and mass spectrometry detection methods. This new column is designed to enable researchers to control the power of high-resolution accurate-mass (HRAM) mass spectrometry at high-throughput rates. The GlycanPac AXR-1 columns are designed to separate both labeled and native glycans based on the availability of samples.

According to the company, this new column helps users achieve increased resolution of glycans using HPLC, providing improved profile characterization. This allows characterization of glycans from monoclonal antibodies being developed for therapeutics.

Thermo Fisher Scientific


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.